SAN FRANCISCO, Sept. 22 /PRNewswire/ -- Dr. Daniel L Minor, a specialist in molecular pharmacology, has been awarded $450,000 by the American Asthma Foundation (AAF). Dr. Minor will turn his expertise to controlling the greatest danger in asthma--the production of lung fluids (mucus) in amounts that flood the airways, causing death by drowning.
Dr. Minor's research into asthma will:
Dr. Minor is Associate Professor of Biochemistry and Biophysics and of Cellular and Molecular Pharmacology at the University of California San Francisco. He is recognized as a leading expert on cell membrane activity.
"These cutting-edge, high risk and potentially breakthrough research projects, like Dr. Minor's, are at the heart of the American Asthma Foundation's approach to funding innovative approaches essential to ending the asthma epidemic," commented Marion O. Sandler, Chairman of the Board. Continuing on, Sandler said, "The American Asthma Foundation awards have produced 17 potential breakthroughs, in less than 10 years, with 11 of these taken up by pharmaceutical companies. After five decades with virtually no improvements, this large number of discoveries in such a brief period of time documents the success of our programs."
Over 23 million, or one in 13 people, in the United States have asthma. More Americans have asthma than coronary heart disease, cancer or Parkinson's disease. Asthma is the most serious chronic disease of childhood and disproportionately strikes the poor.
A brief description of Dr. Minor's project can be seen at www.americanasthmafoundation.org/research-program/2009-research-grant-awardees.
TO ARRANGE AN INTERVIEW WITH AN AAF EXECUTIVE OR RESEARCHER, OR FOR FURTHER INFORMATION, CONTACT:
Seth D. Feldman, Deputy Executive Director, American Asthma Foundation
|SOURCE American Asthma Foundation|
Copyright©2009 PR Newswire.
All rights reserved